Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance and PK of OPC-167832 in healthy males
NCT07314320Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of quabodepistat in Tuberculosis (TB), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Cumulative Amount of OPC-167832 Excreted in Urine at 31 days, Cumulative Amount of OPC-167832 Excreted in Feces at 31 days and 2 more. Started Nov 2023; status: completed.
02
Drugs
quabodepistat
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07314320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07314320.